v3.26.3
Segment and Geographic Information - Schedule of Segment Income of LivaNova’s Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Net revenue $ 393,148 $ 357,753 $ 1,145,993 $ 1,027,132
Cost of sales 128,097 112,898 363,523 327,035
Selling, general, and administrative 154,928 138,522 456,624 405,448
Research and development 47,685 48,577 160,042 133,641
Operating income 28,425 54,012 119,380 156,812
Operating Segments        
Segment Reporting [Line Items]        
Operating income 69,712 80,883 233,020 245,354
Operating Segments | Cardiopulmonary        
Segment Reporting [Line Items]        
Net revenue 225,304 203,218 655,535 578,810
Cost of sales 104,486 98,088 302,680 278,473
Selling, general, and administrative 61,384 58,580 187,698 168,551
Research and development 17,843 18,108 54,014 46,617
3T litigation provision 34,013 3,744 45,346 4,373
Operating income 7,578 24,698 65,797 80,796
Operating Segments | Neuromodulation        
Segment Reporting [Line Items]        
Net revenue 166,127 149,525 484,860 440,088
Cost of sales 18,425 12,693 47,101 40,848
Selling, general, and administrative 55,857 49,937 165,044 148,604
Research and development 29,711 30,710 105,492 86,078
3T litigation provision 0 0 0 0
Operating income $ 62,134 $ 56,185 $ 167,223 $ 164,558